There are the 1) combination trial and the long-run info; and 2) ongoing adjuvant trial which includes Poly ICLC, which is also part of the combination trial.
The adjuvant trial extends beyond GBM to
“Glioma
Anaplastic Astrocytoma
Anaplastic Astro-oligodendroglioma
Glioblastoma”
The DCVax Direct trial had other patients of all kinds.
Then there are many, many patients with many different forms of cancer that have had DCVax-L, some with cancers for which there is no current standard of care and successfully.
As I mentioned, the new standard for extending ti off-label COVERAGE and also for expanding the label, allows for real world evidence. So those efforts will likely continue with other cancers and off-label patients but with the intention likely to expand the label to cancers for which DCVax-L will likely be a great candidate. They will not necessarily need new trials.
Market Data 
Markets 
AI
